For example, c-MET amplification in gastric cancer as well as the autophagy pathway were shown to promote resistance to Src inhibitors59,60 while acquired resistance of ER+ breast cancers to the Src family kinase inhibitor saracatinib is associated with the reactivation of the mammalian target of rapamycin pathway61,62. This evidence concerns the gene MTOR and breast cancer.